Huntington's Disease Trials: Are We Measuring What Matters?
"A New Review Reveals Gaps in How We Assess Treatment Effectiveness"
Huntington's disease (HD) presents a complex challenge for both patients and researchers. The neurodegenerative condition, marked by a combination of motor, cognitive, and psychiatric symptoms, progressively robs individuals of their functional abilities. As research intensifies to find treatments that ease symptoms and slow the disease's course, the critical question arises: are we truly measuring what matters most to those living with HD?
The National Institute of Neurological Disorders and Stroke (NINDS) has taken a significant step by publishing recommendations for selecting measurement tools in HD research. These recommendations aim to standardize and improve the efficiency of clinical trials. However, a recent systematic review casts light on a potential disconnect between recommended measures and those commonly used in practice.
This article breaks down the findings of this review, exploring which outcome measures are most frequently used in Huntington's disease clinical trials, how they align with current recommendations, and why a shift towards patient-centered approaches is essential for future research.
Clinical Trial Design and Outcome Measures
Standard clinical trial design uses unbiased randomization into treatment and placebo-control groups, often with stratification or blocking to balance clinical and demographic characteristics, and may use single-, double-, triple-, or quadruple-blind masking. In Huntington disease, trial success depends substantially on the quality of outcome measures; work using TRACK-HD data proposed a battery of assessments for use as outcomes. A 2023 review noted that clinical trials were still underway three decades after the huntingtin gene was characterized in 1993. Another review argues that HD trial tools and methods need improvement to raise the success rate of drug development.
From Clinical Description to Genetic Discovery
George Huntington first identified the disease in 1872, and the huntingtin gene (HTT) and its role in Huntington’s disease were identified in 1993; genetic testing became available shortly afterward. The history source describes developments in the 1960s as a turning point: after L-DOPA’s benefits in Parkinson’s disease, neurologists met internationally in 1967 to organize a Research Group on Huntington’s Chorea. Research has since expanded substantially, and molecular mechanisms are better understood, although the disease’s pathophysiology remains incompletely understood.
The Clinician's View: A Dominant Perspective
The systematic review, encompassing 151 pharmacological trials, revealed a striking trend: clinician-reported outcomes (ClinROs) dominate the landscape of HD clinical research. A staggering 93% of trials relied on these measures, where clinicians assess and interpret a patient's condition based on their observations and judgment.
- Limited Scope: ClinROs often focus on observable behaviors and functional limitations, potentially overlooking the subtle but significant symptoms that impact a patient's daily life.
- Subjectivity: Clinician's interpretations can introduce bias, potentially missing the nuances of a patient's unique experience.
- Lack of Patient Voice: The patient's direct perspective, including their feelings, unobservable symptoms, and priorities, may be underrepresented.
Measuring Depression, Cognition, and Quality of Life
A systematic review and meta-analysis of depression in Huntington’s disease assessed 6,523 records and included 104 studies, examining depression by functional stage and diagnostic tool as well as its associations with HD-related factors. Research on clinically important cognitive change reports that the amount of cognitive-measure change associated with functionally meaningful decline was greater as disease progressed and as the time frame increased (p < 0.05). HDQLIFE development drew on standardized patient-reported outcome systems, including Neuro-QoL and PROMIS, designed to measure key symptoms and health concepts with reliable, valid measures.
Setbacks in Gene-Targeting Trials
In May 2021, two pharmaceutical companies halted clinical trials of gene-targeting therapies for Huntington’s disease after disappointing performance, despite researchers’ hopes for the approach. A later account characterizes HD research as marked by promising therapeutic approaches that faltered in clinical trials, and says such failures can inform work on safety, patient selection, and trial design. Separately, a clinical review describes antisense oligonucleotide treatment as a strategy then being tested in clinical trials.
Moving Forward: Prioritizing the Patient's Voice
The findings of this systematic review emphasize the urgent need to re-evaluate how we measure treatment success in Huntington's disease clinical trials. While clinician-reported outcomes provide valuable data, they should not be the sole focus.
Choosing the Role of Neuroimaging
Neuroimaging is increasingly included in Huntington’s disease clinical trials for purposes ranging from participant selection and safety monitoring to demonstrating disease modification. The source emphasizes that selecting an imaging modality and its associated analysis tools requires careful consideration. It presents current opinion on neuroimaging’s utility and prospects, underscoring that its contribution depends on matching the method to the trial’s purpose.
Gene Silencing and Emerging Approaches
A 2026 overview describes current research as focused on HTT-lowering therapies, or gene silencing, to reduce toxic mutant protein in the brain; it also says trials and observational studies such as Enroll-HD use biomarkers such as NfL to test these root-cause treatments. A 2025 industry article describes a landscape shifting through gene-targeted therapies, small-molecule modulators, regenerative medicine, and digital innovation. These sources point to several active directions, while the 2026 overview frames HTT lowering as a research focus rather than an established treatment.
Keeping Track of the Trial Landscape
The March 2025 Huntington’s disease clinical trials update is a recurring feature covering ongoing and recently completed HD trials. It also refers readers to a table listing trials previously reviewed in the series. The source describes a continuing effort to track the clinical-trial landscape over time.
Symptoms and Research Participation
A case report describes a middle-aged patient with Huntington’s disease presenting with chorea, cognitive impairment, and psychiatric symptoms, and highlights the clinical features, diagnosis, and management of the condition. The Huntington Study Group describes itself as an HD-focused contract research organization that conducts clinical trials and provides programs intended to affect research and care. Together, these sources illustrate both the varied symptoms described in an individual case and the role of an organization devoted to HD research and care.
To truly understand the impact of new therapies, we must prioritize patient-reported outcomes, ensuring that the voices and experiences of those living with HD are at the forefront of research. This includes:
<ul> <li><b>Developing and validating HD-specific PRO measures:</b> These measures should capture the unique challenges and priorities of individuals with HD.</li> <li><b>Incorporating PROs into clinical trial design:</b> PROs should be included as primary or secondary endpoints, providing a comprehensive assessment of treatment effectiveness.</li> <li><b>Exploring the use of ObsROs:</b> Gathering insights from caregivers and family members can provide a more complete picture of the patient's condition, particularly in later stages of the disease.</li> </ul> By embracing a more patient-centered approach, we can accelerate the development of effective treatments that truly improve the lives of those affected by Huntington's disease.